BMS’ Opdivo plus radiation fails to improve OS in phase 3 brain cancer trial

Image: Bristol-Myers Squibb’s Opdivo plus radiation has failed to improve OS in phase 3 brain cancer trial. Photo: courtesy of Rept0n1x.